Department of Cardiovascular Sciences and NIHR Leicester Biomedical Research Centre, University of Leicester, Leicester, UK.
Department of Cardiology, Poole Hospital NHS Foundation Trust, Poole, UK.
Open Heart. 2023 Aug;10(2). doi: 10.1136/openhrt-2023-002441.
To characterise cardiac remodelling, exercise capacity and fibroinflammatory biomarkers in patients with aortic stenosis (AS) with and without diabetes, and assess the impact of diabetes on outcomes.
Patients with moderate or severe AS with and without diabetes underwent echocardiography, stress cardiovascular magnetic resonance (CMR), cardiopulmonary exercise testing and plasma biomarker analysis. Primary endpoint for survival analysis was a composite of cardiovascular mortality, myocardial infarction, hospitalisation with heart failure, syncope or arrhythmia. Secondary endpoint was all-cause death.
Diabetes (n=56) and non-diabetes groups (n=198) were well matched for age, sex, ethnicity, blood pressure and severity of AS. The diabetes group had higher body mass index, lower estimated glomerular filtration rate and higher rates of hypertension, hyperlipidaemia and symptoms of AS. Biventricular volumes and systolic function were similar, but the diabetes group had higher extracellular volume fraction (25.9%±3.1% vs 24.8%±2.4%, p=0.020), lower myocardial perfusion reserve (2.02±0.75 vs 2.34±0.68, p=0.046) and lower percentage predicted peak oxygen consumption (68%±21% vs 77%±17%, p=0.002) compared with the non-diabetes group. Higher levels of renin (logrenin: 3.27±0.59 vs 2.82±0.69 pg/mL, p<0.001) were found in diabetes. Multivariable Cox regression analysis showed diabetes was not associated with cardiovascular outcomes, but was independently associated with all-cause mortality (HR 2.04, 95% CI 1.05 to 4.00; p=0.037).
In patients with moderate-to-severe AS, diabetes is associated with reduced exercise capacity, increased diffuse myocardial fibrosis and microvascular dysfunction, but not cardiovascular events despite a small increase in mortality.
描述合并和不合并糖尿病的主动脉瓣狭窄(AS)患者的心脏重构、运动能力和纤维炎症生物标志物,并评估糖尿病对结局的影响。
中重度 AS 合并和不合并糖尿病的患者接受超声心动图、压力心血管磁共振(CMR)、心肺运动试验和血浆生物标志物分析。生存分析的主要终点是心血管死亡率、心肌梗死、心力衰竭住院、晕厥或心律失常的复合终点。次要终点是全因死亡。
糖尿病组(n=56)和非糖尿病组(n=198)在年龄、性别、种族、血压和 AS 严重程度方面匹配良好。糖尿病组的体重指数更高,估计肾小球滤过率更低,高血压、高脂血症和 AS 症状的发生率更高。双心室容积和收缩功能相似,但糖尿病组的细胞外容积分数更高(25.9%±3.1%比 24.8%±2.4%,p=0.020),心肌灌注储备更低(2.02±0.75 比 2.34±0.68,p=0.046),最大摄氧量百分比预测值更低(68%±21%比 77%±17%,p=0.002)。糖尿病组的肾素水平较高(log 肾素:3.27±0.59 比 2.82±0.69 pg/mL,p<0.001)。多变量 Cox 回归分析显示,糖尿病与心血管结局无关,但与全因死亡率独立相关(HR 2.04,95%CI 1.05 至 4.00;p=0.037)。
在中重度 AS 患者中,糖尿病与运动能力下降、弥漫性心肌纤维化和微血管功能障碍增加相关,但尽管死亡率略有增加,与心血管事件无关。